Print this page    •   Back to Web version of article

Medical News

Vertex, Merck Hepatitis Drugs Work in HIV Patients

March 8, 2012

Two recently approved hepatitis C virus drugs are effective in patients co-infected with HIV, according to data presented Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle. The new studies involve the HCV protease inhibitors Victrelis (boceprevir) and Incivek (telaprevir).

The new results follow the announcement last month that Victrelis could lessen the efficacy of certain HIV protease inhibitors boosted by ritonavir. The HIV protease inhibitors use the same pathway as the new HCV drugs, so there is a potential for drug interactions, said Dr. Douglas Dietrich, professor of medicine at Mount Sinai School of Medicine in New York.

In a trial involving co-infected patients, 74 percent treated with Incivek, followed by standard HCV therapy ribavirin and interferon, were free of HCV 12 weeks after ending treatment, compared with just 45 percent on standard HCV therapy alone. Viral load did not rebound for any HIV patients on Incivek, which is made by Vertex Pharmaceuticals Inc. The more common side effects included itching, headache, nausea, rash (not severe), fever, and depression.

In the Victrelis trial, 60.7 percent taking it and standard HCV therapy were free of HCV 12 weeks after treatment, compared with 26.5 percent of those on standard HCV therapy alone. Three patients who took Victrelis and four who took only standard therapy had an increase in HIV.

"The drugs that are used to treat HIV have certain metabolic effects," said Eliav Barr, vice president of infectious diseases at Merck, maker of Victrelis. "You have to be careful not to mess with those drug levels."

Vertex said it is now enrolling participants in a Phase III trial investigating Incivek combination regimens among co-infected patients. Merck is conducting a number of Victrelis drug interaction studies and expects within months to start a larger trial in a broader range of HIV patients.

Back to other news for March 2012

Excerpted from:
03.07.2012; Deena Beasley

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.